NCT01243762 is a clinical trial combining MK-2206 and dalotuzumab (monoclonal Ab targeting IGF-1R from Merck), MK-0752 a (Y-secretase inhibitor which inhibits the NOTCH pathway from Merck) and dalotuzumab and MK-8669 (ridaforolimus a mTOR inhibitor from Merck) and dalotuzumab in cancer patients with advanced cancers. This evidence concerns the gene MTOR and cancer.